Microbix Biosystems Inc. (MBXBF)
USD 0.25
(0.0%)
USD 0.25
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -1.12 Million CAD | -130.08% |
| 2022 | 3.32 Million CAD | -34.1% |
| 2021 | 5.38 Million CAD | 3319.4% |
| 2020 | -95.44 Thousand CAD | -90.14% |
| 2019 | 1.53 Million CAD | 110.01% |
| 2018 | -7.07 Million CAD | 336.27% |
| 2017 | -2.79 Million CAD | -126.99% |
| 2016 | 1.25 Million CAD | -17.14% |
| 2015 | 1.51 Million CAD | -12.55% |
| 2014 | 1.72 Million CAD | 47.24% |
| 2013 | 1.3 Million CAD | 202.6% |
| 2012 | -1.25 Million CAD | 2.72% |
| 2011 | -1.08 Million CAD | 1.4% |
| 2010 | -1.19 Million CAD | 9.16% |
| 2009 | -1.31 Million CAD | 58.08% |
| 2008 | -3.13 Million CAD | -51.58% |
| 2007 | -2.06 Million CAD | -23.43% |
| 2006 | -1.67 Million CAD | -627.48% |
| 2005 | 317.6 Thousand CAD | 214.03% |
| 2004 | 101.13 Thousand CAD | 137.13% |
| 2003 | -272.41 Thousand CAD | -202.08% |
| 2002 | 266.86 Thousand CAD | -45.92% |
| 2001 | 493.43 Thousand CAD | 364.87% |
| 2000 | -186.29 Thousand CAD | 95.67% |
| 1999 | -4.4 Million CAD | -152.94% |
| 1998 | -1.9 Million CAD | -1800.0% |
| 1997 | 100 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 591.97 Thousand CAD | 4.75% |
| 2024 Q1 | 2.95 Million CAD | 432.21% |
| 2024 Q2 | 863.21 Thousand CAD | -69.97% |
| 2023 Q2 | 535.41 Thousand CAD | 162.04% |
| 2023 FY | - CAD | -130.08% |
| 2023 Q4 | 2.53 Million CAD | 1125.67% |
| 2023 Q3 | -246.81 Thousand CAD | -146.1% |
| 2023 Q1 | -863.01 Thousand CAD | -1030.93% |
| 2022 Q3 | 1.09 Million CAD | -8.22% |
| 2022 Q4 | 92.7 Thousand CAD | -91.55% |
| 2022 FY | - CAD | -34.1% |
| 2022 Q1 | 1.34 Million CAD | -25.61% |
| 2022 Q2 | 1.19 Million CAD | -11.13% |
| 2021 Q3 | 1.99 Million CAD | 54.66% |
| 2021 FY | - CAD | 3319.4% |
| 2021 Q1 | 567.33 Thousand CAD | 119.01% |
| 2021 Q2 | 1.28 Million CAD | 127.29% |
| 2021 Q4 | 1.8 Million CAD | -9.37% |
| 2020 Q3 | -5195.00 CAD | -102.35% |
| 2020 Q2 | 220.75 Thousand CAD | 248.82% |
| 2020 FY | - CAD | -90.14% |
| 2020 Q4 | -2.98 Million CAD | -57346.37% |
| 2020 Q1 | -148.34 Thousand CAD | -152.56% |
| 2019 Q1 | 278.39 Thousand CAD | 199.07% |
| 2019 Q4 | 282.21 Thousand CAD | 26.7% |
| 2019 Q3 | 222.73 Thousand CAD | -75.12% |
| 2019 Q2 | 895.23 Thousand CAD | 221.57% |
| 2019 FY | - CAD | 110.01% |
| 2018 Q4 | 93.08 Thousand CAD | -76.24% |
| 2018 Q2 | 37.33 Thousand CAD | -86.53% |
| 2018 FY | - CAD | 336.27% |
| 2018 Q1 | 277.14 Thousand CAD | 157.92% |
| 2018 Q3 | 391.73 Thousand CAD | 949.35% |
| 2017 Q4 | -478.52 Thousand CAD | -380.26% |
| 2017 FY | - CAD | -126.99% |
| 2017 Q3 | 170.74 Thousand CAD | -60.57% |
| 2017 Q2 | 433.06 Thousand CAD | 193.42% |
| 2017 Q1 | -463.58 Thousand CAD | -158.43% |
| 2016 Q2 | 459.83 Thousand CAD | 414.11% |
| 2016 FY | - CAD | -17.14% |
| 2016 Q1 | -146.39 Thousand CAD | -139.34% |
| 2016 Q3 | 146.43 Thousand CAD | -68.15% |
| 2016 Q4 | 793.46 Thousand CAD | 441.85% |
| 2015 Q3 | 425.39 Thousand CAD | 34.35% |
| 2015 FY | - CAD | -12.55% |
| 2015 Q2 | 316.62 Thousand CAD | -20.54% |
| 2015 Q1 | 398.46 Thousand CAD | 452.81% |
| 2015 Q4 | 372.15 Thousand CAD | -12.52% |
| 2014 Q4 | 72.08 Thousand CAD | -88.4% |
| 2014 Q3 | 621.19 Thousand CAD | 13.58% |
| 2014 Q1 | 487.34 Thousand CAD | -43.88% |
| 2014 Q2 | 546.91 Thousand CAD | 12.22% |
| 2014 FY | - CAD | 47.24% |
| 2013 FY | - CAD | 202.6% |
| 2013 Q2 | 385.13 Thousand CAD | 210.51% |
| 2013 Q1 | -348.5 Thousand CAD | -144.76% |
| 2013 Q3 | 269.77 Thousand CAD | -29.95% |
| 2013 Q4 | 868.38 Thousand CAD | 221.89% |
| 2012 Q1 | -163.87 Thousand CAD | -6.58% |
| 2012 FY | - CAD | 2.72% |
| 2012 Q2 | -241.9 Thousand CAD | -47.62% |
| 2012 Q4 | -142.38 Thousand CAD | -117.06% |
| 2012 Q3 | 834.79 Thousand CAD | 445.1% |
| 2011 Q3 | -376.17 Thousand CAD | -126.47% |
| 2011 Q4 | -153.75 Thousand CAD | 59.13% |
| 2011 FY | - CAD | 1.4% |
| 2011 Q1 | -381.79 Thousand CAD | -219.96% |
| 2011 Q2 | -166.1 Thousand CAD | 56.49% |
| 2010 Q1 | -390.7 Thousand CAD | -185.14% |
| 2010 Q3 | -896.78 Thousand CAD | -299.52% |
| 2010 Q2 | -224.46 Thousand CAD | 42.55% |
| 2010 FY | - CAD | 9.16% |
| 2010 Q4 | 318.27 Thousand CAD | 135.49% |
| 2009 Q3 | -350.31 Thousand CAD | 35.69% |
| 2009 Q4 | -137.02 Thousand CAD | 60.89% |
| 2009 FY | - CAD | 58.08% |
| 2009 Q2 | -544.72 Thousand CAD | -75.19% |
| 2009 Q1 | -310.93 Thousand CAD | 35.93% |
| 2008 FY | - CAD | -51.58% |
| 2008 Q4 | -485.29 Thousand CAD | 31.62% |
| 2008 Q1 | -840.6 Thousand CAD | -33.86% |
| 2008 Q2 | -1.13 Million CAD | -34.59% |
| 2008 Q3 | -709.7 Thousand CAD | 37.27% |
| 2007 Q4 | -627.97 Thousand CAD | 17.91% |
| 2007 FY | - CAD | -23.43% |
| 2007 Q3 | -765.03 Thousand CAD | -139.59% |
| 2007 Q2 | -319.31 Thousand CAD | 9.62% |
| 2007 Q1 | -353.29 Thousand CAD | 69.96% |
| 2006 FY | - CAD | -627.48% |
| 2006 Q1 | -69.41 Thousand CAD | -966.98% |
| 2006 Q4 | -1.17 Million CAD | -778.62% |
| 2006 Q2 | -294.75 Thousand CAD | -324.61% |
| 2006 Q3 | -133.86 Thousand CAD | 54.58% |
| 2005 Q2 | 152.58 Thousand CAD | 128.33% |
| 2005 Q1 | 66.82 Thousand CAD | -87.4% |
| 2005 Q3 | 104.7 Thousand CAD | -31.38% |
| 2005 Q4 | -6506.00 CAD | -106.21% |
| 2005 FY | - CAD | 214.03% |
| 2004 Q3 | -250.19 Thousand CAD | -489.68% |
| 2004 Q1 | -136.57 Thousand CAD | -126.39% |
| 2004 Q2 | -42.42 Thousand CAD | 68.93% |
| 2004 FY | - CAD | 137.13% |
| 2004 Q4 | 530.33 Thousand CAD | 311.97% |
| 2003 Q3 | -78.38 Thousand CAD | -82.64% |
| 2003 Q2 | -67.96 Thousand CAD | 75.82% |
| 2003 Q1 | -125.98 Thousand CAD | -166.57% |
| 2003 Q4 | -60.32 Thousand CAD | -8.42% |
| 2003 FY | - CAD | -202.08% |
| 2002 Q3 | 127.34 Thousand CAD | 47.95% |
| 2002 FY | - CAD | -45.92% |
| 2002 Q2 | 86.07 Thousand CAD | 163.38% |
| 2002 Q1 | -135.79 Thousand CAD | -332.53% |
| 2002 Q4 | 189.24 Thousand CAD | 48.61% |
| 2001 Q2 | 163.94 Thousand CAD | 7.68% |
| 2001 Q4 | 58.4 Thousand CAD | -52.41% |
| 2001 Q3 | 122.72 Thousand CAD | -25.14% |
| 2001 Q1 | 152.25 Thousand CAD | 1010.94% |
| 2001 FY | - CAD | 364.87% |
| 2000 Q4 | 13.7 Thousand CAD | 0.0% |
| 2000 Q3 | - CAD | 100.0% |
| 2000 Q2 | -200 Thousand CAD | 0.0% |
| 2000 Q1 | - CAD | 100.0% |
| 2000 FY | - CAD | 95.67% |
| 1999 Q3 | -100 Thousand CAD | 80.0% |
| 1999 Q4 | -3.3 Million CAD | -3200.0% |
| 1999 Q1 | -300 Thousand CAD | -250.0% |
| 1999 Q2 | -500 Thousand CAD | -66.67% |
| 1999 FY | - CAD | -152.94% |
| 1998 Q1 | -600 Thousand CAD | -200.0% |
| 1998 FY | - CAD | -1800.0% |
| 1998 Q4 | 200 Thousand CAD | 200.0% |
| 1998 Q3 | -200 Thousand CAD | 81.82% |
| 1998 Q2 | -1.1 Million CAD | -83.33% |
| 1997 FY | - CAD | 0.0% |
| 1997 Q3 | 200 Thousand CAD | 100.0% |
| 1997 Q2 | 100 Thousand CAD | 0.0% |
| 1997 Q4 | -200 Thousand CAD | -200.0% |
| 1997 Q1 | - CAD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 98.421% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | 81.084% |
| SQZ Biotechnologies Company | -64.14 Million USD | 98.251% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 93.543% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 101.193% |
| Mesoblast Limited | -62.38 Million USD | 98.202% |
| Propanc Biopharma, Inc. | -1.53 Million USD | 26.987% |
| Genus plc | 73.7 Million USD | 101.522% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | 83.037% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | 68.381% |
| Marizyme, Inc. | -34.28 Million USD | 96.728% |
| ContraFect Corporation | -64.99 Million USD | 98.275% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | 87.215% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | 75.222% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | 19.995% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | 57.59% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | 51.738% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -116.491% |
| Accustem Sciences Inc. | -3.74 Million USD | 70.064% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 97.674% |
| EV Biologics, Inc. | -1.26 Million USD | 11.491% |
| Q BioMed Inc. | -617.62 Thousand USD | -81.585% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 131.398% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -77.342% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | 50.907% |
| Biomind Labs Inc. | -1.03 Million USD | -8.407% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 111.355% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | 84.339% |
| Skye Bioscience, Inc. | -13.54 Million USD | 91.722% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | 24.599% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -4386.084% |
| Arch Therapeutics, Inc. | -3.88 Million USD | 71.127% |
| IMV Inc. | -35.52 Million USD | 96.843% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 92.933% |
| Curative Biotechnology, Inc. | -2.5 Million USD | 55.174% |
| GB Sciences, Inc. | -1.41 Million USD | 21.013% |
| Alpha Cognition Inc. | -9.7 Million USD | 88.445% |
| HST Global, Inc. | -5303.00 USD | -21048.803% |
| CSL Limited | 4.78 Billion USD | 100.023% |
| Halberd Corporation | -74.27 Thousand USD | -1409.876% |
| Enzolytics Inc. | -2.12 Million USD | 47.149% |
| Resverlogix Corp. | -11.74 Million USD | 90.449% |
| Affymax, Inc. | -14.29 Million USD | 92.154% |
| SYBLEU INC | -141.57 Thousand USD | -692.197% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | 63.385% |
| argenx SE | -216.02 Million USD | 99.481% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 97.973% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 192.155% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | 25.177% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 396.038% |
| AVAX Technologies, Inc. | -6.11 Million USD | 81.652% |
| Zenith Capital Corp. | -8.6 Million USD | 86.968% |
| Genscript Biotech Corporation | -248.71 Million USD | 99.549% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -6337.753% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | 54.157% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -537.14% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 97.171% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | 61.224% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -1.04 Million USD | -7.188% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 16779.372% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | 35.913% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | 41.615% |
| BioStem Technologies, Inc. | -7.55 Million USD | 85.153% |
| ONE Bio Corp. | 13.61 Million USD | 108.239% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -519.324% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| Wesana Health Holdings Inc. | -2.05 Million USD | 45.478% |
| Agentix Corp. | -1.37 Million USD | 18.242% |
| LadRx Corporation | 412.28 Thousand USD | 372.027% |
| Cell Source, Inc. | -4.27 Million USD | 73.75% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -205.408% |
| Regen BioPharma, Inc. | 1.46 Million USD | 176.504% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -19.699% |
| NovAccess Global Inc. | -1.03 Million USD | -8.381% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 112.667% |
| Itoco Inc. | -1.86 Million USD | 39.993% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -195.433% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -0.495% |
| Kadimastem Ltd | -2.62 Million USD | 57.265% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -368.961% |
| CytoDyn Inc. | -18.02 Million USD | 93.779% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -1319.126% |
| Mobile Lads Corp. | -2.24 Million USD | 49.958% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -9070.995% |
| Qrons Inc. | -40.08 Thousand USD | -2698.136% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -130.919% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 312.638% |
| Rebus Holdings, Inc. | -951 Thousand USD | -17.931% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -5.604% |
| International Stem Cell Corporation | 202 Thousand USD | 655.208% |
| Bioxytran, Inc. | -3.82 Million USD | 70.642% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -2030.549% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | 54.445% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 96.873% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -2392.269% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | 59.039% |
| Neutra Corp. | -181.24 Thousand USD | -518.78% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 94.437% |
| PureTech Health plc | -11.62 Million USD | 90.354% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 94.436% |
| IXICO plc | -707 Thousand USD | -58.631% |
| IntelGenx Technologies Corp. | -7.68 Million USD | 85.406% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 97.68% |
| CSL Limited | 4.73 Billion USD | 100.024% |
| Cellectis S.A. | -92.63 Million USD | 98.789% |